argenx SE or Amneal Pharmaceuticals, Inc.: Who Leads in Yearly Revenue?

A Revenue Race: Argenx SE vs. Amneal Pharmaceuticals, Inc.

In the competitive landscape of the pharmaceutical industry, revenue growth is a key indicator of success. Over the past decade, Amneal Pharmaceuticals, Inc. has consistently outpaced Argenx SE in annual revenue. From 2014 to 2023, Amneal's revenue surged by over 200%, reaching a peak of approximately $2.4 billion in 2023. In contrast, Argenx SE, while starting from a modest base, demonstrated impressive growth, particularly in recent years, with a remarkable 2,600% increase, culminating in a revenue of $1.2 billion in 2023.

A Decade of Growth

Amneal's steady climb reflects its robust market presence and strategic expansions. Meanwhile, Argenx's exponential growth, especially post-2020, highlights its innovative breakthroughs in biotechnology. As both companies continue to evolve, investors and industry watchers are keenly observing who will lead the revenue race in the coming years.